Xuwei Zhu

Dr. Xuwei Zhu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2023 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
XZXijie Zhou
Xijie Zhou
CYChenhao Ye
Chenhao Ye
LJliangfu jiang
liangfu jiang
XZXuwei Zhu
Xuwei Zhu
FZFeiya Zhou
Feiya Zhou
YCYiheng Chen
Yiheng Chen

1 January 2024 in Burns & Trauma
Verified
Journal Article
Open access
PDF file
XZXuwei Zhu
Xuwei Zhu
GYGaoxiang Yu
Gaoxiang Yu
YLYa Lv
Ya Lv
NYNingning Yang
Ningning Yang
YZYinuo Zhao
Yinuo Zhao
HXHui Xu
Hui Xu
Background: Ensuring the survival of the distal end of a random flap during hypoperfusion (ischaemia) is difficult in clinical practice. Effective prevention of programmed cell death is a potential strategy for inhibiting ischaemic flap necrosis. The activation of stimulator of interferon genes (STING) pathway promotes inflammation and leads to cell death. The epidermal growth factor family member neuregulin-1 (NRG1) reduces cell death by activating the protein kinase B (AKT) signalling pathway. Moreover, AKT signalling negatively regulates STING activity. We aimed to verify the efficacy of NRG1 injection in protecting against flap necrosis. Additionally, we investigated whether NRG1 effectively enhances ischemic flap survival by inhibiting pyroptosis and necroptosis through STING suppression. Methods: A random-pattern skin flap model was generated on the backs of C57BL/6 mice. The skin flap survival area was determined. The blood supply and vascular network of the flap was assessed by laser Doppler blood flow analysis. Cluster of differentiation 34 immunohistochemistry (IHC) and haematoxylin and eosin (H&E) staining of the flap sections revealed microvessels. Transcriptome sequencing analysis revealed the mechanism by which NRG1 promotes the survival of ischaemic flaps. The levels of angiogenesis, oxidative stress, necroptosis, pyroptosis and indicators associated with signalling pathways in flaps were examined by IHC, immunofluorescence and Western blotting. Packaging adeno-associated virus (AAV) was used to activate STING in flaps. Results: NRG1 promoted the survival of ischaemic flaps. An increased subcutaneous vascular network and neovascularization were found in ischaemic flaps after the application of NRG1. Transcriptomic gene ontology enrichment analysis and protein level detection indicated that necroptosis, pyroptosis and STING activity were reduced in the NRG1 group. The phosphorylation of AKT and forkhead box O3a (FOXO3a) were increased after NRG1 treatment. The increased expression of STING in flaps induced by AAV reversed the therapeutic effect of NRG1. The ability of NRG1 to phosphorylate AKT-FOXO3a, inhibit STING and promote flap survival was abolished after the application of the AKT inhibitor MK2206. Conclusions: NRG1 inhibits pyroptosis and necroptosis by activating the AKT-FOXO3a signalling pathway to suppress STING activation and promote ischaemic flap survival.

19 January 2026 in International Journal of Surgery
Verified
Journal Article
Open access
GYGaoxiang Yu
Gaoxiang Yu
JZJiayi Zhao
Jiayi Zhao
XZXuwei Zhu
Xuwei Zhu
NYNingning Yang
Ningning Yang
JLJunsheng Lou
Junsheng Lou
JQJianjun Qi
Jianjun Qi
Background: Ischemic necrosis frequently affects the distal portion of skin flaps, particularly in diabetic patients. PANoptosis, a form of inflammatory programmed cell death, is implicated in vascular damage. This study examined whether 3,4-dimethoxychalcone (3,4-DC), a novel caloric restriction (CR) mimetic, could inhibit PANoptosis and promote the survival of ischemic and diabetic flaps. Methods: Flap viability was evaluated using laser Doppler blood flow imaging and histological analysis. Western blotting and immunofluorescence were used to assess PANoptosis and autophagy. Quantitative PCR was used to measure microRNA levels. Caspase-1 knockout and db/db mice were used to explore the effects of 3,4-DC on pyroptosis and diabetic complications. Results: 3,4-DC significantly improved ischemic flap survival and enhanced tissue perfusion. PANoptosis was inhibited, and autophagy was activated following 3,4-DC treatment, whereas these effects were abolished by the autophagy inhibitor chloroquine. Transcription factor EB (TFEB) inhibition reduced autophagy and reversed the protective effects of 3,4-DC. miR-107-3p was identified as a 3,4-DC-responsive microRNA that modulates TFEB nuclear translocation through the miR-107-3p/Wnt3a/mTOR pathway. Similar therapeutic effects were observed in diabetic flaps. Conclusion: 3,4-DC promotes the survival of ischemic and diabetic skin flaps by activating autophagy and inhibiting PANoptosis through the miR-107-3p/Wnt3a/mTOR/TFEB axis.

8 April 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
JLJiafeng Li
Jiafeng Li
JLJunsheng Lou
Junsheng Lou
GYGaoxiang Yu
Gaoxiang Yu
YCYijie Chen
Yijie Chen
RCRuiheng Chen
Ruiheng Chen
KZKailiang Zhou
Kailiang Zhou
Increasing evidence indicates that pyroptosis, a new type of programmed cell death, may participate in random flap necrosis and play an important role. ROS-induced lysosome malfunction is an important inducement of pyroptosis. Transcription factor E3 (TFE3) exerts a decisive effect in oxidative metabolism and lysosomal homeostasis. We explored the effect of pyroptosis in random flap necrosis and discussed the effect of TFE3 in modulating pyroptosis. Histological analysis via hematoxylin-eosin staining, immunohistochemistry, general evaluation of flaps, evaluation of tissue edema, and laser Doppler blood flow were employed to determine the survival of the skin flaps. Western blotting, immunofluorescence, and enzyme-linked immunosorbent assays were used to calculate the expressions of pyroptosis, oxidative stress, lysosome function, and the AMPK-MCOLN1 signaling pathway. In cell experiments, HUVEC cells were utilized to ensure the relationship between TFE3, reactive oxygen species (ROS)-induced lysosome malfunction and cell pyroptosis. Our results indicate that pyroptosis exists in the random skin flap model and oxygen and glucose deprivation/reperfusion cell model. In addition, NLRP3-mediated pyroptosis leads to necrosis of the flaps. Moreover, we also found that ischemic flaps can augment the accumulation of ROS, thereby inducing lysosomal malfunction and finally initiating pyroptosis. Meanwhile, we observed that TFE3 levels are interrelated with ROS levels, and overexpression and low expression of TFE3 levels can, respectively, inhibit and promote ROS-induced lysosomal dysfunction and pyroptosis during in vivo and in vitro experiments. In conclusion, we found the activation of TFE3 in random flaps is partially regulated by the AMPK-MCOLN1 signal pathway. Taken together, TFE3 is a key regulator of ROS-induced pyroptosis in random skin flaps, and TFE3 may be a promising therapeutic target for improving random flap survival.

11 July 2024 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
XZXuwei Zhu
Xuwei Zhu
ZCZhenglin Chi
Zhenglin Chi
CYChenhao Ye
Chenhao Ye
RRRasheed Aaman Robinson
Rasheed Aaman Robinson
ZZZongwei Zhou
Zongwei Zhou
YCYiheng Chen
Yiheng Chen

25 June 2026 in European Journal of Pharmacology
Verified
Journal Article
Closed access
XLXian Liu
Xian Liu
JSJingwei Shi
Jingwei Shi
LCLiang Chen
Liang Chen
NYNingning Yang
Ningning Yang
YZYuzhi Zhang
Yuzhi Zhang
JDJian Ding
Jian Ding